Diclofenac (DCF) is a non-steroidal anti-inflammatory drug commonly prescribed to reduce pain in acute and chronic inflammatory diseases. One of the main DCF metabolites is a reactive diclofenac acyl glucuronide (DCF-AG) that covalently binds to biological targets and may contribute to adverse drug reactions arising from DCF use. Cellular efflux of DCF-AG is partially mediated by multidrug resistance-associated proteins (Mrp). The importance of Mrp2 during DCF-induced toxicity has been established, yet the role of Mrp3 remains largely unexplored. In the present work, Mrp3-null (KO) mice were used to study the toxicokinetics and toxicodynamics of DCF and its metabolites. DCF-AG plasma concentrations were 90% lower in KO mice than in wild-type (WT) mice, indicating that Mrp3 mediates DCF-AG basolateral efflux. In contrast, there were no differences in DCF-AG biliary excretion between WT and KO suggesting that only DCF-AG basolateral efflux is compromised by Mrp3 deletion.
Introduction Diclofenac (DCF) is a non-steroidal anti-inflammatory drug (NSAID) that is prescribed to alleviate symptoms associated with ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, and migraine (McNeely and Goa, 1999; Depomed, 2009; Novartis, 2011) . DCF is generally well tolerated although long term usage has been implicated with a variety of adverse events in a subset of patients. The most common side effects of DCF are discomfort, ulceration, and bleeding in the gastrointestinal (GI) tract. These adverse events are related to DCF pharmacodynamics, namely chronic inhibition of cyclooxygenase (COX) enzymes causing a decrease of prostaglandins that protect the GI mucosa (Menasse et al., 1978; Wallace, 2008) .
NSAIDs as a group have a mean liver injury rate of 1 per 100,000 users. However, chronic DCF administration increases the risk of liver injury to 6 per 100,000 users (de Abajo et al., 2004) .
More recently, a meta-analysis of cardiovascular safety implicated DCF with a higher risk of cardiovascular death and stroke among a group of seven NSAIDs (Trelle et al., 2011) .
5 associated with an increased risk of DCF-induced hepatotoxicity compared to UGT2B7*1 homozygotes as the *2 variant possesses higher catalytic activity (Daly et al., 2007) .
DCF-AG is initially formed as a
β -1-O-acyl glucuronide (β-anomer) which can be cleaved by β -glucuronidase into DCF and glucuronic acid.
β -anomers spontaneously isomerize into β -glucuronidase-resistant 2-, 3-, and 4-O-acyl isomers (Sallustio et al., 2000) . DCF-AG undergoes these rearrangements as the pH changes from acidic to physiologic conditions such as those that occur in the GI tract (Ebner et al., 1999; Kenny et al., 2004) . DCF-AG can form adducts with multiple proteins in the liver and GI tract, and dipeptidyl peptidase IV was identified as a DCF-AG target in rat liver where adduction resulted in decreased activity (Hargus et al., 1995) . Furthermore, it was found that broad-acting UGT inhibitors can significantly diminish the covalent binding of DCF metabolite to hepatocellular proteins in vitro (KretzRommel and Boelsterli, 1993) . There is consensus that repeated exposure to DCF-AG contributes to the idiosyncratic drug reaction seen with clinical usage, however the exact nature of how DCF-AG contributes to these idiosyncracies remains unclear.
The potential for DCF-AG to cause extrahepatic covalent binding modifications is contingent upon active transport. For instance, DCF-AG was not detected in the bile of rats
Among the MRPs that are expressed along the basolateral membrane, MRP3 (ABCC3) has been demonstrated to export glucuronide conjugates of other compounds (Zelcer et al., 2001; Zelcer et al., 2006) . In a Caucasian sample pool, fifty-one single nucleotide polymorphisms (SNP) in MRP3 were found (Lang et al., 2004) . A pharmacogenomic study of healthy Japanese subjects identified twenty-one novel SNPs, with two resulting in immature transcript due to insertion of a stop codon (Fukushima-Uesaka et al., 2007) . Gastrointestinal Tract. The gastrointestinal tract was examined histologically with multiple transverse sections of the stomach and large intestine and Swiss Roll sections of the small intestine (Moolenbeek and Ruitenberg, 1981) . Histological examination used a scoring system adapted from a method described by Krieglstein et al. (2007) . Briefly, 3 independent parameters were measured for a combined semi quantitative injury score; the degree of villus/crypt damage, the severity of inflammation (none, minimal, mild, moderate, marked, and severe), and the depth of injury (mucosa with epithelium and lamina propria, submucosa, muscularis, and serosa).
Statistical Analysis. Data are expressed as mean ± standard error of the mean. P values < 0.05 were considered as statistically significant. GraphPad Prism version 6.0 (GraphPad Software Incorporated, La Jolla, CA) was used for statistical analysis of data. Two groups were compared by Student t test. Multiple groups were compared by an analysis of variance followed by
Results
Toxicokinetic Study. In animals that remained anesthetized for surgical exposure of the abdominal cavity and bile duct cannulation, the maximal tolerated dose without morbidity was 75 mg/kg. Plasma concentrations for 75 mg/kg DCF ( Figure 1A ) were significantly higher in KO compared to WT, and the increases were generally less than 40%. Conversely, OH-DCF concentrations in plasma ( Figure 1B ) were significantly higher in WT with a 90% increase observed at 37.5 min. There was a dramatic disparity in plasma concentrations between WT and KO for DCF-AG ( Figure 1C ) with WT having nearly 9-fold higher concentrations in plasma compared to KO. A summary of pertinent toxicokinetic parameters is presented in Table 1 .
Both genotypes had similar estimated DCF plasma concentrations at time zero (C 0 ). Though there was a difference in the DCF elimination half-life (t 1/2 ) between the 2 genotypes, the DCF plasma exposure (AUC 0-tlast ) for WT and KO was comparable.
To determine whether the loss of Mrp3 affected the biliary disposition of DCF and the two metabolites under consideration, the biliary excretion of DCF and its metabolites were quantified. There was no difference in bile flow between WT and KO (data not shown). The biliary excretion of DCF and its metabolites were comparable between the two genotypes ( Figure 1D , E, and F). Of the three analytes, DCF-AG was most predominant in bile constituting nearly 10% of the total DCF dose for each genotype, whereas DCF and OH-DCF biliary to bile for which the major detected analyte was DCF-AG, unchanged DCF in both genotypes was most abundant compared to OH-DCF and DCF-AG.
Clinical Chemistry. Having established a role for Mrp3 to modulate systemic exposure of DCF-AG in vivo, the next objective was to evaluate to susceptibility of KO to DCF-induced injury. For these studies, the DCF dose was increased to 90 mg/kg as that was the maximal nonlethal dose in animals that were non-surgerized and freely moving. Rather than oral gavage, intraperitoneal administration was used to maximize dose absorption and delivery of DCF via portal circulation for immediate uptake into the liver. ALT concentrations ( Figure 3A) were not significantly different between WT and KO suggesting no injuries in the liver. Furthermore, ALT values in all vehicle control and DCF-treated groups were less than 30 U/L, which is the upper limit of normal range for ALT. BUN levels ( Figure 3B ) were statistically higher in KO mice compared to WT, however the lack of difference between vehicle and DCF treated groups in KO mice suggest there was no DCF-induced renal injury.
Histopathology. Histopathological examination of liver and kidneys showed no obvious injuries at the administered dose confirming the clinical chemistry results (data not shown). The small intestines were also examined and scored according to three categories of injury. WT which received DCF showed a trend of higher injury compared to vehicle treated subjects (Figure 4 ), though these differences were not statistically significant. In addition, KO dosed with DCF had significantly greater incidence and severity of erosions and ulcers compared to treatmentmatched WT mice. For both WT and KO, ulcers were observed in the jejunal and ileal but not duodenal regions of the small intestine. Thus, the data suggest that the loss of Mrp3 increased the susceptibility to intestinal injury from an acute dose of DCF.
Immunohistochemistry. Sections of livers, kidneys, and small intestines were subjected to immunohistochemistry in order to determine the extent of DCF adduction. The rationale for conducting this assay was that reactive intermediates or metabolites of DCF are known to covalently bind to proteins. Thus the goal was to establish possible links between covalent binding of reactive DCF products and tissue injury. Kidneys were entirely devoid of DCF adduct staining implying that reactive DCF metabolites were not likely to be generated or accumulated by transit in kidneys (data not shown). In contrast, WT and KO livers showed strong evidence of DCF adduction after DCF administration compared to vehicle controls. The staining was robust and was observed in centrilobular, midzonal, and periportal regions. Vehicle controls did not exhibit staining suggesting that the primary antibody was specific for diclofenac adducts ( Figure 5A ). Interestingly, the livers showed intense staining for DCF adduct yet this organ did not manifest any apparent signs of injury either through clinical chemistry or histopathology. Lastly, compared to small intestines from vehicle controls which were unremarkable ( Figure 5D ), the small intestines from WT and KO also exhibited positive staining of DCF adducts ( Figure 5E-5F ). The level of adduct staining in the small intestine was notably weaker than that observed in the liver as qualitatively assessed by chromagen intensity and the degree of scatter. Adduct formation was detected along the brush border of villi and extended inwards towards the basement membrane. In terms of regiospecificity, staining was scattered throughout the small intestine and did not appear to be confined to any particular location. (Blazka et al., 1995) . This in turn stimulates the migration and infiltration of immune cells into the liver, influencing the ultimate toxic outcome. The role of the immune system in intestinal toxicity following DCF administration was beyond the scope of the present work and will be a focus of future studies.
DCF-AG could adduct enterocyte proteins on the extracellular surface or alternatively adduct from within after uptake by various transporters. Glucuronide conjugates can be transported by organic anion transporting polypeptides (OATPs) of which OATP2B1 is the predominant isoform in the human intestine (Ishiguro et al., 2008; Drozdzik et al., 2014) . It is likely through the mouse Oatp2b1 orthologue, which is also expressed in the intestines, that DCF-AG uptake occurs (Cheng et al., 2005) . Nonetheless, the fact that the liver had intense adduct formation without apparent injury compared to the intestine which had extensive damage but moderate adduction may indicate that protein adducts of DCF metabolite(s) do not necessarily contribute to or cause toxicity.
DCF administration resulted in two diverse outcomes: 1) rapid generation of DCF-AG that was excreted into bile or plasma and 2) COX inhibition that decreased local and/or systemic prostaglandins that protect the GI mucosa. Based on the data, we propose the following series of events to occur in our model of DCF-induced toxicity. DCF-AG is taken up and covalently binds to targets (plasma membrane, intracellular proteins, etc.) compromising the integrity of the enterocyte. In KO, the DCF-AG basolateral efflux is attenuated potentially leading to higher accumulation of intracellular DCF-AG within enterocytes compared to WT. Meanwhile, intestinal mucosal protection is weakened due to DCF's pharmacological inhibition of both COX-1 and COX-2 (Menasse et al., 1978) causing a decrease in protective prostaglandins.
Simultaneously, the highly permeable DCF enters enterocytes and exerts further injury through mitochondrial dysfunction leading to apoptosis (Gomez-Lechon et al., 2003; Lim et al., 2006) .
Unbound DCF-AG may also dissociate into DCF and glucuronic acid intensifying diclofenacinduced mitochondrial dysfunction. Mrp2, which normally confers a measure of protection via DCF-AG efflux, could be affected as Mrp2 translocates intracellularly from its apical membrane localization during oxidative stress (Sekine et al., 2006) . The proposed events would breakdown the overall intactness of the GI tract.
In conclusion, the present work demonstrates that ( -15, 15-30, 30-45, 45-60, 60-75, and 75-90 min) . All data are expressed as mean ± standard error of the mean for 10-12 subjects/group. * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT. 
